コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 diotherapy (control) to 95% at 10 years with adjuvant radiotherapy.
2 ssociated with lower likelihood of receiving adjuvant radiotherapy.
3 d adjuvant cemiplimab, and 17 (26%) received adjuvant radiotherapy.
4 Curative intent surgery +/- adjuvant radiotherapy.
5 arable local control with those who received adjuvant radiotherapy.
6 c antigen follow-up, and 1 patient underwent adjuvant radiotherapy.
7 Local excision margin size and adjuvant radiotherapy.
8 ery (BCS) and endocrine therapy (ET) without adjuvant radiotherapy.
9 0.1%) had at least 1 indication for possible adjuvant radiotherapy.
10 r early breast cancer might gain little from adjuvant radiotherapy.
11 fects on healthy donor tissues and delays to adjuvant radiotherapy.
12 I/II cancers might be managed safely without adjuvant radiotherapy.
13 bloc radical surgical resection, followed by adjuvant radiotherapy.
14 tion that remitted with chemotherapy without adjuvant radiotherapy.
15 A hazard ratio (HR) of less than 1 favoured adjuvant radiotherapy.
16 atients and physicians may consider omitting adjuvant radiotherapy.
17 er breast-conserving surgery with or without adjuvant radiotherapy.
18 lant SR was higher in women who had received adjuvant radiotherapy.
19 t received neoadjuvant treatment, 5 received adjuvant radiotherapy.
20 hat AC is a potentially tractable target for adjuvant radiotherapy.
21 dict risk for LRR and to optimize the use of adjuvant radiotherapy.
22 minant tumors had an improved prognosis with adjuvant radiotherapy.
23 therapy and chemotherapy versus surgery plus adjuvant radiotherapy.
24 0%) to salvage radiotherapy and 697 (50%) to adjuvant radiotherapy.
25 positive surgical margins) may benefit from adjuvant radiotherapy.
26 lity, underwent breast surgery, and received adjuvant radiotherapy.
27 ith a random element to receive de-escalated adjuvant radiotherapy (30-36 Gy in 1.5-1.8 Gy fractions
28 ng proctosigmoidectomy (group 1: n = 101) or adjuvant radiotherapy (40-50 Gy) and resection (group 2:
30 0 years or older were less likely to undergo adjuvant radiotherapy (adjusted OR, 0.69; 95% CI, 0.57-0
32 There is relatively little literature on adjuvant radiotherapy after radical nephroureterectomy w
35 0.89), but a higher probability of receiving adjuvant radiotherapy (aHR = 1.40, 95% CI 1.29-1.52).
36 5 patients were randomly assigned to receive adjuvant radiotherapy and 1078 to a policy of early salv
37 ) between breast cancer survivors exposed to adjuvant radiotherapy and chemotherapy (aRCeBCSs) for pr
38 ver, older patients less frequently received adjuvant radiotherapy and chemotherapy compared with you
40 herapy versus surgery alone, or surgery plus adjuvant radiotherapy and chemotherapy versus surgery pl
42 able to that in patients who did not receive adjuvant radiotherapy and had LE margins larger than 1.0
44 xicity of a 30-36 Gy regimen of de-escalated adjuvant radiotherapy and standard of care treatment.
46 ematic for cancers such as sarcoma for which adjuvant radiotherapy and systemic chemotherapy provide
47 blastoma and is followed by a combination of adjuvant radiotherapy and systemic single-agent chemothe
49 lted in controversy about the optimal use of adjuvant radiotherapy and the timing of sentinel lymph n
52 h as the role of extrapleural pneumonectomy, adjuvant radiotherapy, and use of intensity-modulated ra
53 nted oncologic benefit, use of postoperative adjuvant radiotherapy (aRT) in patients with prostate ca
55 all or cause-specific survival advantage for adjuvant radiotherapy as compared with delayed salvage t
56 dectomy, most patients with seminoma receive adjuvant radiotherapy as standard of care, although surv
57 ular germ cell tumors have been managed with adjuvant radiotherapy, chemotherapy, or retroperitoneal
58 ences in prognosis and treatment response to adjuvant radiotherapy compared to other sites, yet the r
59 e that event-free survival was improved with adjuvant radiotherapy compared with early salvage radiot
61 matic review and meta-analysis suggests that adjuvant radiotherapy does not improve event-free surviv
63 LE margins of 1.0 cm or smaller who received adjuvant radiotherapy experienced OS that was similar to
68 as the standard of care for women requiring adjuvant radiotherapy for invasive early breast cancer.
69 dy was designed to determine the efficacy of adjuvant radiotherapy for patients with pT3N0M0 UTUC.
70 t review to assess the optimal sequencing of adjuvant radiotherapy for such patients undergoing limb-
71 tinence was worse at 1 year for those in the adjuvant radiotherapy group (mean score 4.8 vs 4.0; p=0.
72 % (four of 125 patients) in the de-escalated adjuvant radiotherapy group and 11% (seven of 62 patient
73 atment and analysis (130 in the de-escalated adjuvant radiotherapy group and 64 in the standard of ca
74 2% (two of 125 patients) in the de-escalated adjuvant radiotherapy group and 8% (five of 62 patients)
75 ssion-free survival was 85% for those in the adjuvant radiotherapy group and 88% for those in the sal
76 endpoint (five patients in the de-escalated adjuvant radiotherapy group and two patients in the stan
78 ars was reported in 6% of individuals in the adjuvant radiotherapy group versus 4% in the salvage rad
79 therapy at 5 years was 93% for those in the adjuvant radiotherapy group versus 92% for those in the
80 -free survival, 76 (35.5%) of 214 men in the adjuvant radiotherapy group were diagnosed with metastat
81 or higher toxic effects in the de-escalated adjuvant radiotherapy group were dysphagia (two [2%] of
82 ologic stage I/II, patients who did not have adjuvant radiotherapy had comparable local control with
85 reservation, the addition of chemotherapy to adjuvant radiotherapy, improvement in surgical and radia
86 randomised trials that confirm a benefit of adjuvant radiotherapy in patients with nodal disease at
87 ferences between those omitting vs receiving adjuvant radiotherapy in regards to 2-year rates of over
91 f this study was to determine whether modern adjuvant radiotherapy is associated with increased risk
93 /or studied for most high-grade sarcomas and adjuvant radiotherapy is important for disease control i
94 ccurs at 2.5 years, when the initial cost of adjuvant radiotherapy is matched by the cost generated d
97 or overall stage, histologic risk group, and adjuvant radiotherapy, margin status was not a factor as
98 stage, histologic risk group, and the use of adjuvant radiotherapy, margin status was not an independ
99 the 5-year biochemical recurrence rate using adjuvant radiotherapy may be decreased from approximatel
101 nts were randomly assigned in a 1:1 ratio to adjuvant radiotherapy or an observation policy with salv
104 r obtaining an additional PET/CT scan before adjuvant radiotherapy or concurrent chemoradiotherapy (C
107 ictors for PFS by multivariate analysis were adjuvant radiotherapy (P = 0.010; HR, 0.39; 95% CI, 0.20
108 surgery with the recommendation of omitting adjuvant radiotherapy (partial de-escalation) on the bas
109 ore inputs can be a potential supplement for adjuvant radiotherapy patient selection of IDH-mutant gl
110 ere independent of tumor subsite, receipt of adjuvant radiotherapy, positive pathologic margins, or a
111 imed to identify a five-fraction schedule of adjuvant radiotherapy (radiation therapy) delivered in 1
113 for pathologically advanced prostate cancer, adjuvant radiotherapy resulted in significantly reduced
116 oma in situ (DCIS) is routinely treated with adjuvant radiotherapy (RT) after breast-conserving surge
117 h early-stage breast cancer are treated with adjuvant radiotherapy (RT) after breast-conserving surge
118 e is conflicting evidence for the benefit of adjuvant radiotherapy (RT) after resection of pancreatic
121 S were treated with limb-sparing surgery and adjuvant radiotherapy (RT) at a single institution.
123 scalation from 60 to 66 Gy to 30 to 36 Gy of adjuvant radiotherapy (RT) for selected patients with hu
128 ed doxorubicin-based NAC; 205 (88%) received adjuvant radiotherapy (RT), and 164 (70%) also received
131 ard refinements in the methods of delivering adjuvant radiotherapy that provide shorter, more conveni
132 en in an advanced-stage, intermediate-grade, adjuvant radiotherapy to bulky sites may improve outcome
133 le reviews the rationale and indications for adjuvant radiotherapy to the breast and regional lymph n
134 aimed to compare the efficacy and safety of adjuvant radiotherapy versus an observation policy with
135 eligible if they aimed to compare immediate adjuvant radiotherapy versus early salvage radiotherapy,
139 f LE clinical margins larger than 1.0 cm and adjuvant radiotherapy was associated with the highest OS
142 internal control group (observation, n=61); adjuvant radiotherapy was more common in the control gro
143 n period 1 to 34.3% in period 4), the use of adjuvant radiotherapy was reduced by half (12.9% to 6.0%
144 ould have sufficient power to assess whether adjuvant radiotherapy was superior to early salvage radi
145 m RCTs demonstrates a survival detriment for adjuvant radiotherapy with limited evidence for a reduct
147 was no significant difference in the use of adjuvant radiotherapy with or without chemotherapy or ne